Cited by 276SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies

The DOI matches its Crossref record; 92 of the 100 references it cites were found in a registry or an index; none of the 47 sources its claims cite is checked for support yet.

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Open access

Amanat, Fatima, Thapa, Mahima, Lei, Tinting, Ahmed, Shaza M. Sayed, Adelsberg, Daniel C., Carreño, Juan Manuel, Strohmeier, Shirin, Schmitz, Aaron J., Zafar, Sarah, Zhou, Julian Q., Rijnink, Willemijn, Alshammary, Hala, Borcherding, Nicholas, Reiche, Ana Gonzalez, Srivastava, Komal, Sordillo, Emilia Mia, van Bakel, Harm, Ahmed, Bulbul, Altman, Deena, Amoako, Angela, Awawda, Mahmoud, Beach, Katherine, Bermúdez-González, Carolina, Chernet, Rachel, Eaker, Lily, Fabre, Shelcie, Ferreri, Emily D., Floda, Daniel, Gleason, Charles, Kleiner, Giulio, Jurczyszak, Denise, Matthews, Julia, Mendez, Wanni, Mulder, Lubbertus C.F., Polanco, Jose, Russo, Kayla, Salimbangon, Ashley, Saksena, Miti, Shin, Amber S., Sominsky, Levy, Suthakaran, Sayahi, Wajnberg, Ania, Turner, Jackson S., Bajic, Goran, Simon, Viviana, Ellebedy, Ali H., Krammer, Florian·2021·Cell

DOI 10.1016/j.cell.2021.06.005PMC PMC8185186

Open this paper in CoChat — free account Open PDF

Abstract

In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to spikes of seasonal human coronaviruses OC43 and HKU1. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine-induced RBD binding antibodies may provide substantial protection against viral variants carrying single E484K RBD mutations.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.06.005

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 47 cited sources checked · 0 supported · 0 flagged

A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the majority of vaccine-induced antibodies did not have neutralizing activity”
- Also stated in: § The majority of isolated mAbs from SARS-CoV2 vaccinees are non-neutralizing · plain
  “Only a minority of the binding antibodies, even those targeting the RBD, showed neutralizing activity”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Abstract
Load-bearingStrength:plain· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike”
- Also stated in: § The plasmablast response to SARS-CoV-2 mRNA vaccination targets both the RBD and the NTD · hedged
  “These data indicate that RBD and NTD are co-dominant in the context of the mRNA-induced plasmablast response.”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Abstract
Load-bearingStrength:plain· not yet calibratedCausal:correlational· not yet calibratedn = 3
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes

Show all 89 claims

It may state two separate claims as one. 37
Probably not a substantial claim. 35

None of the sources cited for this claim have been checked yet.
In the paper
“It has been reported that SARS-CoV-2 infection induces an original antigenic sin-type immune response against human coronaviruses (hCoVs) to which the majority of the human population has pre-existing immunity”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Results > mRNA vaccination induces a modest but measurable immune response to seasonal β-coronavirus spike proteins
What the sources say
- Not checked yetcites Aydillo et al., 2021 source
- Not checked yetcites Song et al., 2020
Load-bearingStrength:plain· not yet calibratedCausal:direct· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
Probably not a substantial claim.
In the paper
“This is also true for B cells and monoclonal antibodies (mAbs) isolated from vaccinated individuals”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Introduction
What the sources say
- Not checked yetcites Wang et al., 2021 source
Load-bearingStrength:plain· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
Probably not a substantial claim.
In the paper
“Antibodies binding to the RBD can potently block attachment of the virus to ACE2 and thereby neutralize the virus”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Introduction
What the sources say
- Not checked yetcites Barnes et al., 2020 source
Load-bearingStrength:plain· not yet calibratedCausal:direct· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“it directly interacts with the cellular receptor angiotensin converting enzyme 2 (ACE2) which mediates host cell entry”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Introduction
What the sources say
- Not checked yetcites Letko et al., 2020 source
- Not checked yetcites Wrapp et al., 2020 source
Load-bearingStrength:plain· not yet calibratedCausal:direct· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
Probably not a substantial claim.
In the paper
“These data were already apparent in the early phase clinical trials but remained unrecognized at the time”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Walsh et al., 2020
Strength:plain· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Two recent studies have performed a similarly unbiased plasmablast analysis for individuals naturally infected with SARS-CoV-2”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Cho et al., 2021
- Not checked yetcites Huang et al., 2021
Strength:plain· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passes
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“has already been shown for natural infection with SARS-CoV-2 where a “backboost” to β-coronaviruses was also found (Aydillo et al., 2021; Song et al., 2020).”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Aydillo et al., 2021 source
- Not checked yetcites Song et al., 2020
Strength:boosted· not yet calibratedCausal:direct· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passes
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“a recent deep mutational scanning paper with sera from mRNA-1273 vaccinees found a very strong RBD-focused response (Greaney et al., 2021a).”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Greaney et al., 2021a
Strength:boosted· not yet calibratedCausal:correlational· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passes
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Recent studies analyzing the plasmablast response after natural infection have found a similar co-dominance of RBD and NTD (Cho et al., 2021; Huang et al., 2021)”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Cho et al., 2021
- Not checked yetcites Huang et al., 2021
Strength:plain· not yet calibratedCausal:correlational· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passes
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“it is substantial and occurs during a time when neutralizing antibody titers are either very low or absent (Baden et al., 2020; Dagan et al., 2021; Polack et al., 2020).”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Baden et al., 2020 source
- Not checked yetcites Dagan et al., 2021 source
- Not checked yetcites Polack et al., 2020 source
Load-bearingStrength:plain· not yet calibratedCausal:correlational· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Increased affinity as an escape mechanism for viruses has been described in the past (Hensley et al., 2009; O’Donnell et al., 2012)”
§ SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 > Discussion
What the sources say
- Not checked yetcites Hensley et al., 2009 source
- Not checked yetcites O’Donnell et al., 2012 source
Strength:plain· not yet calibratedCausal:direct· not yet calibrated
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passes
Probably not a substantial claim. The paper’s conclusions may not depend on it.

66 of 66

The paper relies on this without support.
All viral variants of concern are heavily mutated in the NTD region.
“Since all viral variants of concern are heavily mutated in this region”

1 of 1

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

Convalescent antibody ratios are interpreted in opposite directions
Major
The results say lower-titer convalescent individuals had more binding relative to neutralizing antibodies. The discussion instead says low-titer serum had the highest relative amount of neutralizing antibodies and higher-titer serum had more binding antibodies.
Figure caption names a different variant
Minor
The Figure 4 caption lists B.1.315 among the three variants of concern, while the introduction lists B.1.351 in its place.

2 of 2

Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656 · cited 2×
“Similarly, encouraging data have been published on both the plasmablast response and the memory B cell response induced by SARS-CoV-2 infection (Dan et al., 2021; Gaebler et al., 2020; Guthmiller et al., 2021; Huang et al., 2021; Robbiani et al., 2020; Rodda et al., 2021; Wilson et al., 2020).”
Self-citation
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581 · cited 9×
“IgG1 was by far the most (A) Mutations of the three major variants of concern B.1.1.7, B.1.315, and P.1.”
Influential
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557

Flagged first, then by citations

Show all 100 references

8 of the 100 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Annavajhala, 2021, A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York, medRxiv

Sorted by citations

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
Turner, J. S., O’Halloran, J. A., Kalaidina, E., Kim, W., Schmitz, A. J., Zhou, J. Q., Lei, T., Thapa, M., Chen, R. E., Case, J. B., et al. (2021) · Nature · doi:10.1038/s41586-021-03738-2 · Cited by 831
Self-citation
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 462
Self-citation
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients
Lu, L., Mok, B. W.-Y., Chen, L. L., Chan, J. M. C., Tsang, O. T. Y., Lam, B. H. S., Chuang, V. W., Chu, A. W., Chan, W. M., Ip, J. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1041 · Cited by 396
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Heinz, F. X., & Stiasny, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00369-6 · Cited by 378
Principles and therapeutic applications of adaptive immunity
Chi, H., Pepper, M., & Thomas, P. G. (2024) · Cell · doi:10.1016/j.cell.2024.03.037 · Cited by 394
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Cho, A., Muecksch, F., Schaefer-Babajew, D. J., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · Nature · doi:10.1038/s41586-021-04060-7 · Cited by 263
Broadly neutralizing antibodies target the coronavirus fusion peptide
Dacon, C., Tucker, C., Peng, L., Lee, C.-C. D., Lin, T.-H., Yuan, M., Cong, Y., Wang, L., Purser, L., Williams, J. K., et al. (2022) · Science · doi:10.1126/science.abq3773 · Cited by 250
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection
Israel, A., Shenhar, Y., Green, I., Merzon, E., Golan‐Cohen, A., Schäffer, A. A., Ruppin, E., Vinker, S., & Magen, E. (2021) · Vaccines · doi:10.3390/vaccines10010064 · Cited by 225
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Zhang, A., Stacey, H. D., D’Agostino, M. R., Tugg, Y., Marzok, A., & Miller, M. S. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00813-1 · Cited by 225
Learning from prepandemic data to forecast viral escape
Thadani, N. N., Gurev, S. F., Notin, P., Youssef, N., Rollins, N. J., Ritter, D., Sander, C., Gal, Y., & Marks, D. S. (2023) · Nature · doi:10.1038/s41586-023-06617-0 · Cited by 233
The humoral response and antibodies against SARS-CoV-2 infection
Qi, H., Liu, B., Wang, X., & Zhang, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01248-5 · Cited by 195
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
(2022) · doi:10.1016/j.cell.2022.01.027 · Cited by 179
SARS-CoV-2 vaccination induces mucosal antibody responses in previously infected individuals
Sano, K., Bhavsar, D., Singh, G., Floda, D. L., Srivastava, K., Gleason, C., PARIS Study Group, Amoako, A. A., Andre, D., Beach, K. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32389-8 · Cited by 167
Self-citation
Defining the risk of SARS-CoV-2 variants on immune protection
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., Alter, G., Amara, R. R., Baric, R. S., Barouch, D. H., et al. (2022) · Nature · doi:10.1038/s41586-022-04690-5 · Cited by 168
Self-citation
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Alsoussi, W. B., Malladi, S. K., Zhou, J. Q., Liu, Z., Ying, B., Kim, W., Schmitz, A. J., Lei, T., Horvath, S. C., Sturtz, A. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06025-4 · Cited by 174
Self-citation
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
Scheaffer, S. M., Lee, D., Whitener, B., Ying, B., Wu, K., Liang, C.-Y., Jani, H., Martin, P., Amato, N. J., Avena, L. E., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02092-8 · Cited by 169
T-Cell and Antibody Responses to First BNT162b2 Vaccine Dose in Previously SARS-CoV-2-Infected and Infection-Naive UK Healthcare Workers: A Multicentre, Prospective, Observational Cohort Study
Angyal, A., Longet, S., Moore, S. C., Payne, R., Harding, A. C., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., et al. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00275-5 · Cited by 182
Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects
Wheeler, S., Shurin, G. V., Yost, M., Anderson, A., Pinto, L., Wells, A. H., & Shurin, M. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00341-21 · Cited by 156
Antibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 150
Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins
Wang, Z., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H.-H., Ramos, V., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.003 · Cited by 145
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
Srivastava, K., Carreño, J. M., Gleason, C., Monahan, B., Singh, G., Abbad, A., Tcheou, J., Raskin, A. J., Kleiner, G., van Bakel, H., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.017 · Cited by 162
Self-citation
Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2Preprint
Liu, L., Iketani, S., Guo, Y., Chan, J. F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472719 · Cited by 142
Scientific rationale for developing potent RBD-based vaccines targeting COVID-19
Kleanthous, H., Silverman, J. M., Makar, K. W., Yoon, I.-K., Jackson, N. M., & Vaughn, D. W. (2021) · npj Vaccines · doi:10.1038/s41541-021-00393-6 · Cited by 139
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 149
mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
Kapłonek, P., Cizmeci, D., Fischinger, S., Collier, A.-R. Y., Suscovich, T. J., Linde, C., Broge, T. A., Mann, C. J., Amanat, F., Dayal, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm2311 · Cited by 136
Self-citation
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
Mackin, S., Desai, P., Whitener, B. M., Karl, C. E., Liu, M., Baric, R. S., Edwards, D. K., Chicz, T. M., McNamara, R. P., Alter, G., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01359-1 · Cited by 123
Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity
Aguilar-Bretones, M., Fouchier, R. A. M., Koopmans, M., & van Nierop, G. P. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162192 · Cited by 108
Cryo-EM structure of the SARS-CoV-2 Omicron spike
Cerutti, G., Guo, Y., Liu, L., Liu, L., Zhang, Z., Luo, Y., Huang, Y., Wang, H. H., Ho, D. D., Sheng, Z., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110428 · Cited by 108
RETRACTED: SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3715 · Cited by 100
Retracted
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/d41586-021-03846-z · Cited by 114
Self-citation
Single-cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine
Sureshchandra, S., Lewis, S. A., Doratt, B. M., Jankeel, A., Coimbra Ibraim, I., & Messaoudi, I. (2021) · JCI Insight · doi:10.1172/jci.insight.153201 · Cited by 91
B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101
The origins of COVID‐19 pandemic: A brief overview
Hao, Y., Wang, Y., Wang, M.-Y., Zhou, L., Shi, J., Cao, J., & Wang, D. (2022) · Transboundary and Emerging Diseases · doi:10.1111/tbed.14732 · Cited by 139
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.037 · Cited by 109
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
Self-citation
Cross-protective immunity following coronavirus vaccination and coronavirus infection
Dangi, T., Palacio, N. M., Sanchez, S., Park, M., Class, J., Visvabharathy, L., Ciucci, T., Koralnik, I. J., Richner, J. M., & Penaloza-MacMaster, P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151969 · Cited by 79
Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity
Gong, S. Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D., Goyette, G., Gendron‐Lepage, G., et al. (2021) · Virology · doi:10.1016/j.virol.2021.09.001 · Cited by 81
Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines
Liang, C.-Y., Raju, S., Liu, Z., Li, Y., Arunkumar, G. A., Case, J. B., Scheaffer, S. M., Zost, S. J., Acreman, C. M., Gagné, M., et al. (2024) · Nature · doi:10.1038/s41586-024-07539-1 · Cited by 92
Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
Kaku, C. I., Champney, E. R., Normark, J., García, M., Johnson, C. E., Ahlm, C., Christ, W., Sakharkar, M., Ackerman, M. E., Klingström, J., et al. (2022) · Science · doi:10.1126/science.abn2688 · Cited by 75
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
Richardson, S. I., Manamela, N. P., Motsoeneng, B. M., Kaldine, H., Ayres, F., Makhado, Z., Mennen, M., Skelem, S., Williams, N., Sullivan, N. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100510 · Cited by 73
SARS-CoV-2 spike S2-specific neutralizing antibodies
Li, C., & Chang, S. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2220582 · Cited by 73
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 62
Self-citation
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72
Self-citation
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Immune imprinting and next-generation coronavirus vaccines
Huang, C. Q., Vishwanath, S., Carnell, G., Chan, A. C. Y., & Heeney, J. L. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01505-9 · Cited by 68
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Carreño, J. M., Alshammary, H., Singh, G., Raskin, A. J., Amanat, F., Amoako, A. A., Gonzalez-Reiche, A. S., van de Guchte, A., PARIS study group, Awawda, M. H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103626 · Cited by 61
Self-citation
BNT162b2 vaccine induces divergent B cell responses to SARS-CoV-2 S1 and S2
Brewer, R. C., Ramadoss, N. S., Lahey, L. J., Jahanbani, S., Robinson, W. H., & Lanz, T. V. (2021) · Nature Immunology · doi:10.1038/s41590-021-01088-9 · Cited by 62
A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike
Claireaux, M. A. F., Caniels, T. G., de Gast, M., Han, J., Guerra, D., Kerster, G., van Schaik, B. D. C., Jongejan, A., Schriek, A. I., Grobben, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32232-0 · Cited by 64
The role of vaccines in the COVID-19 pandemic: what have we learned?
Krammer, F. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00996-2 · Cited by 66
Self-citation
A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets
van de Ven, K., Lanfermeijer, J., van Dijken, H., Muramatsu, H., de Melo, C. V. B., Lenz, S., Peters, F., Beattie, M. B., Lin, P. J. C., Ferreira, J. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.adc9937 · Cited by 66
B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination
Kotagiri, P., Mescia, F., Rae, W. M., Bergamaschi, L., Tuong, Z. K., Turner, L., Hunter, K., Gerber, P. P., Hosmillo, M. D. T., Hess, C., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110393 · Cited by 61
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Structure and inhibition of SARS-CoV-2 spike refolding in membranes
Grunst, M. W., Qin, Z., Dodero‐Rojas, E., Ding, S., Prévost, J., Chen, Y., Hu, Y., Pazgier, M., Wu, S., Xie, X., et al. (2024) · Science · doi:10.1126/science.adn5658 · Cited by 61
Protective neutralizing epitopes in SARS‐CoV‐2
Liu, H., & Wilson, I. A. (2022) · Immunological Reviews · doi:10.1111/imr.13084 · Cited by 49
Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
Crowley, A. R., Natarajan, H., Hederman, A. P., Bobak, C. A., Weiner, J. A., Wieland-Alter, W., Lee, J., Bloch, E. M., Tobian, A. A. R., Redd, A. D., et al. (2022) · eLife · doi:10.7554/elife.75228 · Cited by 51
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussières, G., Bo, Y., Ding, S., Laumaea, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110429 · Cited by 46
A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
Maeda, R., Fujita, J., Konishi, Y., Kazuma, Y., Yamazaki, H., Anzai, I., Watanabe, T., Yamaguchi, K., Kasai, K., Nagata, K., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03630-3 · Cited by 47
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
Voss, W. N., Mallory, M. L., Byrne, P. O., Marchioni, J., Knudson, S. A., Powers, J. M., Leist, S. R., Dadonaite, B., Townsend, D. R., Kain, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101668 · Cited by 44
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
McNaughton, A. L., Paton, R. S., Edmans, M. D., Youngs, J., Wellens, J., Phalora, P. K., Fyfe, A. J., Belij‐Rammerstorfer, S., Bolton, J. S., Ball, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156372 · Cited by 46
Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
Peng, L., Hu, Y., Mankowski, M. C., Ren, P., Chen, R. E., Wei, J., Zhao, M., Li, T., Tripler, T. N., Ye, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29288-3 · Cited by 43
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Clark, J. J., Hoxie, I., Adelsberg, D. C., Sapse, I. A., Andreata‐Santos, R., Yong, J. S., Amanat, F., Tcheou, J., Raskin, A. J., Singh, G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114922 · Cited by 43
Self-citation
Single-Cell Technologies for the Study of Antibody-Secreting Cells
Broketa, M., & Bruhns, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821729 · Cited by 42
Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations
Cohen, L., Spiro, D. J., & Viboud, C. G. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010591 · Cited by 42
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
Lenart, K., Hellgren, F., Ols, S., Yan, X., Cagigi, A., Cerveira, R. A., Winge, I. P., Hanczak, J., Mueller, S. O., Jasny, E., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.001 · Cited by 40
Cross-protection induced by highly conserved human B, CD4+, and CD8+ T-cell epitopes-based vaccine against severe infection, disease, and death caused by multiple SARS-CoV-2 variants of concern
Prakash, S., Dhanushkodi, N. R., Zayou, L., Ibraim, I. C., Quadiri, A., Coulon, P.-G. A., Tifrea, D. F., Suzer, B., Shaik, A. M., Chilukuri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328905 · Cited by 42
Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike
Changrob, S., Fu, Y., Guthmiller, J. J., Halfmann, P., Li, L., Stamper, C. T., Dugan, H. L., Accola, M., Rehrauer, W., Zheng, N.-Y., et al. (2021) · mBio · doi:10.1128/mbio.02975-21 · Cited by 40
Self-citation
Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination
Cho, A., Muecksch, F., Schaefer-Babajew, D., Wang, Z., Finkin, S., Gaebler, C., Ramos, V., Cipolla, M., Mendoza, P., Agudelo, M., et al. (2021) · doi:10.1101/2021.07.29.454333 · Cited by 275
SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations
Anderson, E. M., Li, S. H., Awofolaju, M., Eilola, T., Goodwin, E. C., Bolton, M. J., Gouma, S., Manzoni, T. B., Hicks, P. D., Goel, R. R., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111496 · Cited by 37
COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant women
Atyeo, C. G., Shook, L. L., Nziza, N., DeRiso, E. A., Muir, C., Baez, A. M., Lima, R. S., Demidkin, S., Brigida, S. M., Guzman, R. M. D., et al. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.014 · Cited by 37
Boosting with Omicron-matched or historical mRNA vaccines increases neutralizing antibody responses and protection against B.1.1.529 infection in micePreprint
Ying, B., Scheaffer, S. M., Whitener, B. M., Liang, C.-Y., Dmytrenko, O., Mackin, S., Wu, K., Lee, D. W., Avena, L. E., Chong, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479419 · Cited by 35
Protective non-neutralizing SARS-CoV-2 monoclonal antibodies
Izadi, A., & Nordenfelt, P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.06.003 · Cited by 36
The impact of COVID-19 in pregnancy: Part II. Vaccination to pregnant women
Wang, P., Lee, W.-L., Yang, S., Tsui, K., Chang, C., & Lee, F. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000612 · Cited by 31
Antibody escape and global spread of SARS-CoV-2 lineage A.27
Kaleta, T., Kern, L., Hong, S. L., Hölzer, M., Kochs, G., Beer, J., Schnepf, D., Schwemmle, M., Bollen, N., Kolb, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28766-y · Cited by 33
Regenerable and high-throughput surface plasmon resonance assay for rapid screening of anti-SARS-CoV-2 antibody in serum samples
Jiang, M., Dong, T., Han, C., Liu, L., Zhang, T., Kang, Q., Wang, P., & Zhou, F. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339830 · Cited by 31
Molecular Mimicry of the Viral Spike in the SARS-CoV-2 Vaccine Possibly Triggers Transient Dysregulation of ACE2, Leading to Vascular and Coagulation Dysfunction Similar to SARS-CoV-2 Infection
Devaux, C. A., & Camoin‐Jau, L. (2023) · Viruses · doi:10.3390/v15051045 · Cited by 34
Hybrid immunity expands the functional humoral footprint of both mRNA and vector-based SARS-CoV-2 vaccines
Kapłonek, P., Deng, Y., Lee, J. S.-L., Zar, H. J., Zavadska, D., Johnson, M., Lauffenburger, D. A., Goldblatt, D., & Alter, G. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101048 · Cited by 32
Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination
Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38
Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells
Fischer, K., Lulla, A., So, T. Y., Pereyra-Gerber, P., Raybould, M. I. J., Kohler, T. N., Yam‐Puc, J. C., Kamiński, T. S., Hughes, R., Pyeatt, G. L., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02346-5 · Cited by 39
Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
Andreano, E., Paciello, I., Marchese, S., Donnici, L., Pierleoni, G., Piccini, G., Manganaro, N., Pantano, E., Abbiento, V., Pileri, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31115-8 · Cited by 30
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179
Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats
Tcheou, J., Raskin, A. J., Singh, G., Kawabata, H., Bielak, D. A., Sun, W., González‐Domínguez, I., Sather, D. N., García‐Sastre, A., Palese, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791764 · Cited by 28
Self-citation
Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic
Heiskanen, A., Galipeau, Y., Little, J., Mortimer, L., Ramotar, K., Langlois, M., & Cooper, C. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13065 · Cited by 30
Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variants
Montgomerie, I., Bird, T. W., Palmer, O. R., Mason, N. C., Pankhurst, T. E., Lawley, B., Hernández, L. C., Harfoot, R., Authier-Hall, A., Anderson, D. E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106256 · Cited by 27
Combination of S1–N–Terminal and S1–C–Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus
Yang, D., Su, M., Guo, D., Zhao, F., Wang, M., Liu, J., Zhou, J., Sun, Y., Yang, X., Qi, S., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00809 · Cited by 27
Self-citation
The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination
Rijkers, G. T., & van Overveld, F. J. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.10.001 · Cited by 27
Nanovaccines for Advancing Long-Lasting Immunity against Infectious Diseases
Gao, X., Wang, X., Li, S., Rahman, M. S. U., Xu, S., & Liu, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07741 · Cited by 27
Global Epidemiology and Seasonality of Human Seasonal Coronaviruses: A Systematic Review
Wilson, R., Kovacs, D., Crosby, M., & Ho, A. Y. W. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae418 · Cited by 31
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients
Nitahara, Y., Nakagama, Y., Kaku, N., Candray, K., Michimuko, Y., Tshibangu-Kabamba, E., Kaneko, A., Yamamoto, H., Mizobata, Y., Kakeya, H., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00965-21 · Cited by 25
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variantPreprint
Scheaffer, S. M., Lee, D. W., Whitener, B. M., Ying, B., Wu, K., Jani, H., Martin, P., Amato, N. J., Avena, L. E., Berrueta, D. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.12.507614 · Cited by 26
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
Lenart, K., Cerveira, R. A., Hellgren, F., Ols, S., Sheward, D. J., Kim, C., Cagigi, A., Gagné, M., Davis, B. J., Germosen, D., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00806-2 · Cited by 26
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
Lawrenz, J., Xie, Q., Zech, F., Weil, T., Seidel, A., Krnavek, D., van der Hoek, L., Münch, J., Müller, J. A., & Kirchhoff, F. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac057 · Cited by 25
Binding and neutralizing antibody responses to SARS-CoV-2 in very young children exceed those in adults
Karron, R. A., Quesada, M. G., Schappell, E., Schmidt, S. D., Knoll, M. D., Hetrich, M. K., Veguilla, V., Doria‐Rose, N. A., Dawood, F. S., & SEARCh Study Team (2022) · JCI Insight · doi:10.1172/jci.insight.157963 · Cited by 25
Structure of a Vaccine-Induced, Germline-Encoded Human Antibody Defines a Neutralizing Epitope on the SARS-CoV-2 Spike N-Terminal Domain
Altomare, C. G., Adelsberg, D. C., Carreño, J. M., Sapse, I. A., Amanat, F., Ellebedy, A. H., Simon, V. R., Krammer, F., & Bajic, G. (2022) · mBio · doi:10.1128/mbio.03580-21 · Cited by 24
Self-citation
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses
Bedi, R., Bayless, N. L., & Glanville, J. (2023) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020722-041304 · Cited by 26
Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
Wang, B., Goh, Y. S., Fong, S., Young, B. E., Ngoh, E. Z. X., Chavatte, J., Salleh, S. N. M., Yeo, N. K., Amrun, S. N., Hor, P. X., et al. (2021) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2021.100276 · Cited by 23
Discovery and characterization of a pan-betacoronavirus S2-binding antibody
Johnson, N. V., Wall, S. C., Kramer, K. J., Holt, C., Periasamy, S., Richardson, S. I., Manamela, N. P., Suryadevara, N., Andreano, E., Paciello, I., et al. (2024) · Structure · doi:10.1016/j.str.2024.08.022 · Cited by 26
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice
Halfmann, P., Patel, R. S., Loeffler, K., Yasuhara, A., de Velde, L.-A. V., Yang, J. E., Chervin, J. C., Troxell, C. A., Huang, M., Zheng, N., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55824-y · Cited by 23

Authors: Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., Rijnink, W., Alshammary, H., Borcherding, N., Reiche, A. G., Srivastava, K., Sordillo, E. M., van Bakel, H., Ahmed, B., Altman, D., Amoako, A., Awawda, M., Beach, K., Bermúdez-González, C., Chernet, R., Eaker, L., Fabre, S., Ferreri, E. D., Floda, D., Gleason, C., Kleiner, G., Jurczyszak, D., Matthews, J., Mendez, W., Mulder, L. C. F., Polanco, J., Russo, K., Salimbangon, A., Saksena, M., Shin, A. S., Sominsky, L., Suthakaran, S., Wajnberg, A., Turner, J. S., Bajic, G., Simon, V., Ellebedy, A. H., & Krammer, F.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Washington University in St. Louis (US)
AbCellera (Canada) (CA)
Corresponding author: Bajic, Goran
Simon, Viviana
Ellebedy, Ali H.
Krammer, Florian
ORCID: Amanat, Fatima
Thapa, Mahima
Ahmed, Shaza M. Sayed
Adelsberg, Daniel C.
Carreño, Juan Manuel
Strohmeier, Shirin
Schmitz, Aaron J.
Zafar, Sarah
Zhou, Julian Q.
Rijnink, Willemijn
Alshammary, Hala
Borcherding, Nicholas
Reiche, Ana Gonzalez
Sordillo, Emilia Mia
van Bakel, Harm
Altman, Deena
Amoako, Angela
Beach, Katherine
Chernet, Rachel
Fabre, Shelcie
Ferreri, Emily D.
Gleason, Charles
Kleiner, Giulio
Jurczyszak, Denise
Mulder, Lubbertus C.F.
Saksena, Miti
Sominsky, Levy
Suthakaran, Sayahi
Wajnberg, Ania
Turner, Jackson S.
Bajic, Goran
Simon, Viviana
Ellebedy, Ali H.
Krammer, Florian
Venue: Cell
Publisher: Elsevier BV
Published: 2021-07
Volume: 184
Issue: 15
Pages: 3936-3948.e10
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2021.06.005
PMC: PMC8185186
OpenAlex: W3171375949
Cited by: 273
References: 100
Citations by year: 2026: 15 · 2025: 25 · 2024: 36 · 2023: 52 · 2022: 94 · 2021: 51
FWCI: 18.53
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 386 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cell (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Open Philanthropy Project (2020-215611)
JPB Foundation (5384, 5T32CA009547)
NIAID (5T32CA009547, 75N93019C00051, U01AI141990, U01AI150747, HHSN272201400006C)
AbbVie
Icahn School of Medicine at Mount Sinai
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, mRNA vaccines, spike protein, N-terminal domain, receptor binding domain, S2 subunit, polyclonal antibodies, monoclonal antibodies, neutralizing antibodies, original antigenic sin, seasonal human coronaviruses, antibody response
MeSH terms: Protein Domains, Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Monoclonal, Antibodies, Viral, Antibody Formation, Binding, Competitive, Humans, Immunoglobulin G, Mutation, RNA, Messenger, Vaccination, Amino Acid Substitution, Somatic Hypermutation, Immunoglobulin, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks